South Rampart Pharma is a company in the field of clinical-stage life sciences with a focus on enhancing the safe management of pain through the development of innovative small-molecule remedies that can mitigate numerous risks associated with current pain relief medications. The organization's series of fresh compounds has effectively lessened both pain and fever in preliminary research without inducing liver and kidney toxicity, which is common with existing non-opioid analgesics. The primary program, SRP-3D (Diethylamide [DA]), is presently undergoing Phase 1 assessment to evaluate its safety, tolerability, and pharmacokinetics, with data anticipated in the latter half of 2022.